UOC
KALV

UBS O'Connor’s KalVista Pharmaceuticals KALV Stock Holding History

UBS O'Connor’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-79,460
Closed -$898K – 377
2025
Q2 		$898K Sell
79,460
-90,232
-53% -$1.1M 0.03% 234
2025
Q1 		$1.96M Sell
169,692
-3,001
-2% -$30.6K 0.05% 126
2024
Q4 		$1.46M Buy
172,693
+37,141
+27% +$385K 0.04% 195
2024
Q3 		$1.57M Buy
135,552
+12,592
+10% +$158K 0.04% 211
2024
Q2 		$1.45M Buy
122,960
+40,960
+50% +$478K 0.04% 240
2024
Q1 		$973K Buy
+82,000
New +$1.09M 0.03% 278

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return